A Study to Evaluate the Safety, Tolerability, and Efficacy of Escalating Doses of BMS-986463 in Participants With Select Advanced Malignant Tumors.

NCT06476808 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

240

Enrollment

INDUSTRY

Sponsor class

Conditions

High-grade Serous Ovarian Carcinoma (HGSOC)
Uterine Serous Carcinoma (USC)
Non-small Cell Lung Cancer (NSCLC)

Interventions

DRUG: BMS-986463

Sponsor

Bristol-Myers Squibb